



October 19, 2023

## News Release

Company name: TMS Co., Ltd.  
Name of representative: Takuro Wakabayashi, Chief Executive Officer  
(Securities code: 4891; Growth Market)

### **TMS Co., Ltd. entered into Joint Research Agreement with Teikyo University**

TMS Co., Ltd. (the “Company”) announces today that the Company has completed the process for entering into a Joint Research Agreement with Teikyo University (Itabashi, Tokyo) with regard to exploratory research to identify biomarkers for renal function.

In this joint research, both parties will conduct metabolome-based screening to identify biomarkers that are indicative of effects on the recovery from renal impairment.

Impact of this joint research agreement on the Company's business performance for the current fiscal year is expected to be minimal.

#### **About TMS Co., Ltd.**

TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address unmet medical needs. The Company’s pipeline consists of a family of small compounds called SMTPs (*Stachybotrys microspora* triprenyl phenols) derived from a fungus. The lead pipeline compound, TMS-007, is indicated for the treatment of acute ischemic stroke. It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipeline products by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/>.

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Investor and Media Contact:  
[ir@tms-japan.co.jp](mailto:ir@tms-japan.co.jp)

End